Enveda Analysis: $308M Raised
What is Enveda?
Enveda specializes in drug discovery by leveraging the hidden chemistry of nature. Their platform enables rapid identification and characterization of natural molecules, significantly reducing the time and cost associated with traditional methods. This innovative approach aims to transform the pharmaceutical landscape by accelerating the development of effective medicines.
HQ Country
Boulder, United States
Employees
201-500
Founded
2019
Industry
Biotech, HealthTech, Data Analytics
Product Features & Capabilities
- Platform for rapid drug discovery from natural sources
- Advanced analytics for molecular characterization
- Proprietary technology for identifying natural compounds
- High-throughput screening for drug candidates
- Data-driven insights for pharmaceutical development
How much Enveda raised
Series C - $130 million
November 21, 2024Lead Investor: Kinnevik, FPV, Baillie Gifford, Premji Invest, among others.
Series B and B1 - $55 million (part of a total of $119 million for Series B and B1)
June 17, 2024Lead Investor: Premji Invest, Lingotto Investment Management.
Series B2 - $55 million
June 14, 2024Lead Investor: Premji Invest, Lingotto Investment Fund, Microsoft, The Nature Conservancy, Kinnevik, True Ventures.
Series B (combined equity and debt financing) - $68 million
December 21, 2022Lead Investor: Dimension, FPV, Jazz Venture Partners, True Ventures, Lux Capital.
Financial Overview
$308MTotal Raised
Series C$130 million
November 21, 2024
Investors: Kinnevik, FPV, Baillie Gifford, Premji Invest, among others.
Series B and B1$55 million (part of a total of $119 million for Series B and B1)
June 17, 2024
Investors: Premji Invest, Lingotto Investment Management.
Series B2$55 million
June 14, 2024
Investors: Premji Invest, Lingotto Investment Fund, Microsoft, The Nature Conservancy, Kinnevik, True Ventures.
Series B (combined equity and debt financing)$68 million
December 21, 2022
Investors: Dimension, FPV, Jazz Venture Partners, True Ventures, Lux Capital.
